RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease

被引:51
|
作者
Mandigo, Amy C. [1 ]
Yuan, Wei [2 ,3 ]
Xu, Kexin [4 ]
Gallagher, Peter [1 ]
Pang, Angel [5 ,6 ]
Guan, Yi Fang [5 ,6 ]
Shafi, Ayesha A. [1 ]
Thangavel, Chellappagounder [7 ,8 ,9 ,10 ,11 ]
Sheehan, Beshara [2 ,3 ]
Bogdan, Denisa [2 ,3 ]
Paschalis, Alec [2 ,3 ]
McCann, Jennifer J. [1 ]
Laufer, Talya S. [1 ]
Gordon, Nicolas [1 ]
Vasilevskaya, Irina A. [1 ]
Dylgjeri, Emanuela [1 ]
Chand, Saswati N. [1 ]
Schiewer, Matthew J. [1 ]
Domingo-Domenech, Josep [1 ]
Den, Robert B. [1 ,7 ,8 ,9 ,11 ]
Holst, Jeff [5 ,6 ]
McCue, Peter A. [1 ,11 ]
de Bono, Johann S. [2 ,3 ]
McNair, Christopher [1 ,11 ]
Knudsen, Karen E. [1 ,7 ,8 ,9 ,11 ]
机构
[1] Thomas Jefferson Univ, Dept Canc Biol, Philadelphia, PA 19107 USA
[2] Inst Canc Res, London, England
[3] Royal Marsden NHS Fdn Trust, London, England
[4] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA
[5] Univ New South Wales, Sch Med Sci, Sydney, NSW, Australia
[6] Univ New South Wales, Prince Wales Clin Sch, Sydney, NSW, Australia
[7] Thomas Jefferson Univ, Dept Urol, Philadelphia, PA 19107 USA
[8] Thomas Jefferson Univ, Dept Med Oncol, Philadelphia, PA 19107 USA
[9] Thomas Jefferson Univ, Dept Radiat Oncol, Philadelphia, PA 19107 USA
[10] Thomas Jefferson Univ, Dept Dermatol, Philadelphia, PA 19107 USA
[11] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA
关键词
TUMOR-SUPPRESSOR STATUS; AMINO-ACID-TRANSPORT; BREAST-CANCER; THERAPEUTIC RESPONSE; RETINOBLASTOMA GENE; RB-PATHWAY; EXPRESSION; CYCLE; INHIBITION; RECEPTOR;
D O I
10.1158/2159-8290.CD-20-1114
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Loss of the retinoblastoma (RB) tumor suppressor protein is a critical step in reprogramming biological networks that drive cancer progression, although mechanistic insight has been largely limited to the impact of RB loss on cell-cycle regulation. Here, isogenic modeling of RB loss identified disease stage-specific rewiring of E2F1 function, providing the first-in-field mapping of the E2F1 cistrome and transcriptome after RB loss across disease progression. Biochemical and functional assessment using both in vitro and in vivo models identified an unexpected, prominent role for E2F1 in regulation of redox metabolism after RB loss, driving an increase in the synthesis of the antioxidant glutathione, specific to advanced disease. These E2F1-dependent events resulted in protection from reactive oxygen species in response to therapeutic intervention. On balance, these findings reveal novel pathways through which RB loss promotes cancer progression and highlight potentially new nodes of intervention for treating RB-deficient cancers. SIGNIFICANCE: This study identifies stage-specific consequences of RB loss across cancer progression that have a direct impact on tumor response to clinically utilized therapeutics. The study herein is the first to investigate the effect of RB loss on global metabolic regulation and link RB/E2F1 to redox control in multiple advanced diseases.
引用
收藏
页码:2334 / 2353
页数:20
相关论文
共 50 条
  • [1] E2F1, a Novel Regulator of Metabolism
    Denechaud, Pierre-Damien
    Fajas, Lluis
    Giralt, Albert
    FRONTIERS IN ENDOCRINOLOGY, 2017, 8
  • [2] RB/E2F1 in the crossroad of autophagy and apoptosis
    Jiang, Hong
    Martin, Vanesa
    Gomez-Manzano, Candelaria
    Johnson, David G.
    Alonso, Marta
    White, Erin J.
    Xu, Jing
    McDonnell, Timothy J.
    Shinojinna, Naoki
    Fueyo, Juan
    CANCER RESEARCH, 2010, 70
  • [3] Differential impact of RB status on E2F1 reprogramming in human cancer
    McNair, Christopher
    Xu, Kexin
    Mandigo, Amy C.
    Benelli, Matteo
    Leiby, Benjamin
    Rodrigues, Daniel
    Lindberg, Johan
    Gronberg, Henrik
    Crespo, Mateus
    De Laere, Bram
    Dirix, Luc
    Visakorpi, Tapio
    Li, Fugen
    Feng, Felix Y.
    de Bono, Johann
    Demichelis, Francesca
    Rubin, Mark A.
    Brown, Myles
    Knudsen, Karen E.
    CANCER RESEARCH, 2018, 78 (16) : 100 - 100
  • [4] RB loss-induced genome wide E2F1 reprogramming drive advanced prostate cancer
    McNair, Christopher
    Xu, Kexin
    Mandigo, Amy
    Benelli, Matteo
    Leiby, Benjamin
    Rodrigues, Daniel
    Lindberg, Johan
    Gronberg, Henrik
    Visakorpi, Tapio
    Li, Fugen
    De Bono, Johann
    Demichelis, Francesca
    Rubin, Mark
    Brown, Myles
    Knudsen, Karen E.
    CANCER RESEARCH, 2017, 77
  • [5] Differential impact of RB status on E2F1 reprogramming in human cancer
    McNair, Christopher
    Xu, Kexin
    Mandigo, Amy C.
    Benelli, Matteo
    Leiby, Benjamin
    Rodrigues, Daniel
    Lindberg, Johan
    Gronberg, Henrik
    Crespo, Mateus
    De laere, Bram
    Dirix, Luc
    Visakorpi, Tapio
    Li, Fugen
    Feng, Felix Y.
    de Bono, Johann
    Demichelis, Francesca
    Rubin, Mark A.
    Brown, Myles
    Knudsen, Karen E.
    JOURNAL OF CLINICAL INVESTIGATION, 2018, 128 (01): : 341 - 358
  • [6] E2F1: a promising regulator in ovarian carcinoma
    Zhan, Lei
    Zhang, Yu
    Wang, Wenyan
    Song, Enxue
    Fan, Yijun
    Wei, Bing
    TUMOR BIOLOGY, 2016, 37 (03) : 2823 - 2831
  • [7] THE ROLE OF E2F1 IN CHOLESTEROL METABOLISM
    Lai, Q.
    Coll, L. Fajas
    ATHEROSCLEROSIS, 2015, 241 (01) : E66 - E66
  • [8] Disease stage specific recalibration of E2F1 function after RB loss
    Mandigo, Amy C.
    McNair, Chris
    Xu, Kexin
    Li, Fugen
    Schiewer, Matthew J.
    Brown, Myles
    Knudsen, Karen E.
    CANCER RESEARCH, 2018, 78 (16) : 100 - 101
  • [9] Transcriptional activation of the senescence regulator Lsh by E2F1
    Niu, Jing
    Chen, Tianda
    Han, Limin
    Wang, Pan
    Li, Na
    Tong, Tanjun
    MECHANISMS OF AGEING AND DEVELOPMENT, 2011, 132 (04) : 180 - 186
  • [10] Identification of E2F1 as a positive transcriptional regulator for δ-catenin
    Kim, Kwonseop
    Oh, Minsoo
    Ki, Flyunkyoung
    Wang, Tao
    Bareiss, Sonja
    Fini, M. Elizabeth
    Li, Dawei
    Lu, Qun
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 369 (02) : 414 - 420